Table 3.

Immunological response in subjects who received AstraZeneca

	Withhold therapy	Continue therapy	Controls	Total
Detectable SARS-CoV2 Ab*
Post first vaccine dose	21/31 (67.7)	9/33 (27.3)	19/24 (79.2)	49/88 (55.68)
Withhold versus continue (p=0.002)
Withhold versus controls (p=0.380)
Continue versus controls (p=0.000)
Post second vaccine dose	27/27 (100)	36/43 (83.7)	22/22 (100)	85/92 (92.39)
Withhold versus continue (p=0.038)
Withhold versus controls
Continue versus controls (p=0.000)
Mean SARS-CoV2 Ab titre†
Post first vaccine dose	2.17 (2.32)	1.25 (1.58)	6.50 (11.47)	3.00 (6.51)
Withhold versus continue (p=0.014)	1.4 (2.7)	0.5 (0.6)	2.1 (5.05)	0.95 (2.25)
Withhold versus controls (p=0.105)
Continue versus controls (p=0.000)
Post second vaccine dose	26.55 (33.00)	14.70 (22.73)	13.10 (11.53)	17.79 (24.76)
Withhold versus continue (p=0.086)	7.7 (46.5)	4.9 (18.1)	10.6 (13.2)	6.5 (19.9)
Withhold versus controls (p=0.709)
Continue versus controls (p=0.119)

Data are presented as proportions (%) or mean (SD) and median (IQR).

*Using Fisher’s exact test with significance cut-off 5%.

†Using Wilcoxon-Mann-Whitney U test with significance cut-off 5%.

Ab, antibody.